Topic: biomedical research
China’s Shanghai Pharma is planning to open an R&D unit in San Diego as part of an international expansion drive that could also include acquisitions in the U.S. and Europe.
We all love a top 10: It serves as a definitive "best of the best," and sometimes a look at the top of the chart can reflect the state of an industry.
If you took charge of a sizable biopharma company in 2017, there was one thing you had to do.
Andreas Busch is heading for Shire after exiting Bayer.
After penning research deals potentially worth billions of dollars this month, German pharma Bayer is looking internally as it rings in the changes.
The Infectious Diseases Society of America warns that potential new tax changes could hit biomedical research in major public health areas.
The ex-chief medical officer of uniQure has left his post and moved over to the small, rare-disease biotech Therachon.
AstraZeneca and MedImmune have hired a clutch of new cancer R&D execs.
Neon has signed a new R&D pact with gene-editing biotech CRISPR Therapeutics.
We delve into the R&D strategy for Allergan, a company that nearly became part of Pfizer last year.